Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy
Platinum Sensitive · BRCA Mutated · Relapsed Ovarian Cancer · Following Complete or Partial Response to Platinum Based Chemotherapy
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 327 (final count)
- Started
- Sep 3, 2013
- Main results expected
- Sep 19, 2016
- Fully finished
- Dec 31, 2026
- Results posted
- Feb 7, 2018
What counts as success
The trial's main goal(s), called the “primary outcome.”
Progression Free Survival (PFS) Using Investigator Assessment According to Modified Response Evaluation Criteria In Solid Tumours (RECIST 1.1)
Measured over: Radiologic scans performed at baseline then every ~12 weeks up to 72 weeks, then every ~ 24 weeks thereafter until objective radiological disease progression. Assessed until 19 Sep 2016 DCO (16 Jan 2017 DCO for China Cohort); up to a maximum of 36 months.
Changes Tremor has spotted
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT01874353 · record last updated 2026-07-29 · checked 2026-11-09 15:47 UTC